Comparison of the gastric acid inhibition function among lansoprazole, pantoprazole, and their respective stereoisomers in healthy Chinese subjects.
Yu L, Sun LN, Zhang XH, Xu YH, Zhang HW, Shen YW, Xie LJ, Wang MF, Jiao HW, Li YQ, Wang YQ, Liu Y.
Int J Clin Pharmacol Ther. 2019 Nov;57(11):552-560. doi: 10.5414/CP203514.

Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L, Liu J, Zheng Y, Zhai Y, Lin M, Wu G, Lv D, Shentu J.
Clin Drug Investig. 2019 Oct;39(10):953-965. doi: 10.1007/s40261-019-00824-2.

Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Habu Y.
Intern Med. 2019 Sep 1;58(17):2427-2433. doi: 10.2169/internalmedicine.2535-18.

Diagnosis and treatment of laryngopharyngeal reflux: Use of empirical lansoprazole.
Batioglu-Karaaltin A, Develioglu O, Akiner U, Kulekci M.
Ear Nose Throat J. 2018 Dec;97(12):E1-E6.

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E.
World J Gastroenterol. 2018 Apr 14;24(14):1550-1561. doi: 10.3748/wjg.v24.i14.1550.

Comparison of oral and intravenous lansoprazole for the prevention of bleeding from artificial ulcers after endoscopic submucosal dissection for gastric tumors: a prospective randomized phase II study (KDOG 0802).
Ishido K, Tanabe S, Azuma M, Katada C, Wada T, Yano T, Koizumi W.
Surg Endosc. 2018 Jun;32(6):2939-2947. doi: 10.1007/s00464-017-6008-9.

Lansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent.
Mdanda S, Baijnath S, Shobo A, Singh SD, Maguire GEM, Kruger HG, Arvidsson PI, Naicker T, Govender T.
Biomed Chromatogr. 2017 Dec;31(12). doi: 10.1002/bmc.4035.

Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets.
Chono S, Matsui M, Nakamura K, Kasai R.
J Pharm (Cairo). 2016;2016:6131608. doi: 10.1155/2016/6131608.

Safety

Lansoprazole as an uncommon cause of anaphylaxis: What to give next?
Aydin AA, Bilge S, Duzenli T, Aslan H, Aydin G.
North Clin Istanb. 2018 Aug 8;6(3):315-316. doi: 10.14744/nci.2018.36539.

Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin.
Zhang Y, Shi D, Abagyan R, Dai W, Dong M.
Interdiscip Sci. 2019 Jun;11(2):273-281. doi: 10.1007/s12539-019-00335-w.

Lansoprazole is a chemical compound, a benzimidazole sulphoxide derivative is a member of the pyridines and benzimidazoles.

It occurs as a fine, white powder.

What it is used for and where

Take only under medical supervision

It is one of the proton pump inhibitors (omeprazole, pantoprazole, esomeprazole, rabeprazole and ilaprazole) as a potent inhibitor of gastric acid secretion and is widely used for the treatment of gastroesophageal reflux, dyspepsia and peptic ulcer (1).

It's one of the well tolerated drugs and since it has a certain sensitivity to acids, it is normally administered in the form of capsules containing granules coated with enteric substances to prevent gastric decomposition and to increase bioavailability.

Due to its anti-inflammatory properties, it inhibits the induction of various inflammatory mediators, thus preventing acute liver damage (2).

Lansoprazole supplementation (50 mg/kgBW) for 4 weeks produced significant decreases in the renal cyst  and an improvement in renal function through the reduction of plasma creatinine and blood urea nitrogen (3).

Like all drugs it can cause side effects. Always consult your doctor.

Lansoprazole studies

Typical commercial product characteristics Lansoprazole 

Appearance	White powder
Boiling Point	555.8±60.0 °C at 760 mmHg
Melting Point	178-182°C dec.
Flash Point	289.9±32.9°C
Density	1.5±0.1 g/cm3
Loss on drying	≤2.0%
Heavy metals	≤10 ppm
Water	≤1.0%
Sulphated ash	≤0.5%/g
Residue on ignition	≤0.1%
Safety

• Molecular Formula  C₁₆H₁₄F₃N₃O₂S
• Molecular Weight  369.4 g/mol
• Exact Mass   369.075867
• CAS: 103577-45-3   138530-94-6
• UNII    0K5C5T2QPG
• EC Number   2017-001-1
• DSSTox Substance ID  DTXSID4023200
• IUPAC  2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)  
• InChl Key      MJIHNNLFOKEZEW-UHFFFAOYSA-N
• SMILES   CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
• NSC    758710    758638
• MDL number MFCD00866873
• PubChem Substance ID 329750232

Synonyms:

• Prevacid
• Lanzopral
• Blason
• Takepron
• Ketian
• Zoton
• Lancid
• Lansoprazolum
• Lanston
• Lanproton
• Prezal
• Lansopep
• Ulpax
• Lasoprol
• Lanz
• Mesactol
• Bamalite
• Pro Ulco
• Monolitum
• Lanzol
• Lansoprazol
• Lanzul
• Agopton
• PrevOnco
• Limpidex
• Lanzo
• Ogastro
• Biuret Gr
• Lanzor
• 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
• 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
• 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
• 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
• 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
• 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
• 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
• 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
• 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
• 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
• 2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
• 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
• 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
• 2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole

References________________________________________

(1) Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)]. Inatomi N, Nitta K, Sakurai Y. Nihon Yakurigaku Zasshi. 2008 Feb;131(2):149-56.

(2) The Proton Pump Inhibitor Lansoprazole Has Hepatoprotective Effects in In Vitro and In Vivo Rat Models of Acute Liver Injury. Nakatake R, Hishikawa H, Kotsuka M, Ishizaki M, Matsui K, Nishizawa M, Yoshizawa K, Kaibori M, Okumura T. Dig Dis Sci. 2019 Oct;64(10):2854-2866. doi: 10.1007/s10620-019-05622-6.

(3)  Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion.  Nantavishit J, Chatsudthipong V, Soodvilai S.  Biochem Pharmacol. 2018 Aug;154:175-182. doi: 10.1016/j.bcp.2018.05.005.